Emergence of Mucormycosis during COVID-19 Pandemic and Dermatological Manifestations

Mucormycosis is a ubiquitously present angioinvasive fungus in the environment. [1] Though uncommon in immunocompetent patients, the extended survival of critically ill and immunocompromised patients, uncontrolled diabetes mellitus, persons living with HIV, and indiscriminate use of systemic antimicrobials has led to an upsurge of systemic mucormycosis in recent years. [2] Mucormycosis is known since 1885 when it was first described by Paltauf. Later in 1943 Gregory et al. reported the first case of rhino-orbital -cerebral mucormycosis. The term “mucormycosis” was coined by an American pathologist R. D. Baker. [3] The term “Black fungus” is a misnomer and should not be used to describe mucormycosis by scientific community as “black fungus” or “dematiaceous fungi” is used for fungi causing phaeohyphomycosis.

Cutaneous involvement is the third most common manifestation of systemic mucormycosis. [4] However, unlike systemic mucormycosis, primary cutaneous mucormycosis is not uncommon in immunocompetent individuals, who account for 40%–50% of such cases. [5] There has been a renewed interest in mucormycosis recently, due to its association with COVID-19 infection.

COVID-19 and Mucormycosis

During the pandemic of COVID-19, an unprecedented increase in the incidence of mucormycosis has been noted in India. COVID-19-associated mucormycosis (CAM) is now recognized as an epidemic in itself and is declared as a notifiable disease. Already >30,000 cases of CAM have been notified in India. [6] A large multicentric study performed during the first wave of COVID-19 (March 2020-March 2021) from India has revealed a 2.1 time increase of mucormycosis compared to same period before COVID-19 (non CAM cases). [7]

Uncontrolled diabetes mellitus is the most common cause reported in all the studies, [1,4,8] followed by history of prolonged use of corticosteroids. In 1/3rd of the patients with CAM, COVID-19 was the only underlying disease, of them majority (78%) received corticosteroids during the management of COVID-19. [7] It is interesting to note that in 20% of CAM cases, diabetes mellitus was detected for the first time during the COVID-19 pandemic suggesting the role of SARS-COV2 in causing diabetes mellitus. [7] Other risk factors such as malignancies or organ transplantation were negligible. Rhino-orbital mucormycosis is the commonest presentation followed by rhino cerebral and pulmonary mucormycosis. [7] Rhizopus arrhizus is the commonest species isolated from CAM cases followed by Rhizomucor pusillus, Apophysomyces variabilis, and Lichtheimia corymbifera. [7] The mortality rate (at 6 weeks) in the CAM (38%) is lesser than the non-CAM cases (45%). [7]

Dermatological Manifestations of COVID-19

The ongoing COVID-19 pandemic has drawn the attention of dermatologists towards a broad spectrum of cutaneous manifestations of SARS-COV2 infection classified into five major clinical patterns: pseudo-chilblain like eruption, vesicular eruption, urticarial eruption, maculopapular eruption including pityriasis rosea like, perifollicular eruption, erythema multiforme like, pseudovesicular or resembling erythema elevatum diutinum, purpuric eruptions, morbilliform eruptions and livedoid/necrotic lesions. [9] In addition, a plethora of cutaneous reactions including local injection site reactions, urticarial eruptions, morbilliform eruptions, erythromelalgia, delayed inflammatory reaction to hyaluronic acid fillers, chilblains, zoster, herpes simplex flares and pityriasis rosea like reaction have been documented after administration of COVID-19 vaccines. [10-12]

Dermatological Manifestations of Mucormycosis

Cutaneous involvement in mucormycosis occurs either due to direct inoculation of the fungus by penetrating trauma (primary mucormycosis), dissemination from blood-borne infection (secondary mucormycosis), or through the contiguous spread. [13] Broadly, primary cutaneous mucormycosis have two distinct presentations; a rapidly progressive angioinvasive necrotising type and the lesser-known gradually progressive chronic granulomatous type. The classification of cutaneous mucormycosis is depicted in Table 1 and the difference between acute necrotising mucormycosis and chronic granulomatous mucormycosis is depicted in Table 2. [13]

Primary Mucormycosis

Acute necrotising type

This type of primary cutaneous mucormycosis is commonly seen in immunosuppressed individuals and begin at the site of trauma, most common being road traffic accidents, farm accidents, nosocomial use of adhesives, and sites of venepuncture. [14] Morphologically, it presents variably as erythematous macules, pustules, infiltrative plaques, and retiform lesions. These lesions then rapidly progress to cutaneous ulcers and necrotic eschar with a jagged margin. If left untreated, dissemination of the fungus by angioinvasion and death is likely. Other morphological variants include eczema gangrenosum like lesions,
cellulitic plaques, bull’s-eye infarcts and targetoid plaques, and pyoderma gangrenosum like lesions.[2] Dermatological patients with ulcers and raw skin can acquire mucormycosis directly from the environment and a high index of suspicion is generally required when encountered with non-healing skin ulcers.[15]

**Chronic granulomatous type**

This uncommon variant is less well documented in the literature. The epidemiological data show that this presentation is most commonly reported from Asia, with majority of the cases documented from China and India.[13,16] Unlike acute necrotising type, most of the patients of chronic granulomatous mucormycosis are immunocompetent and trauma is an important risk factor for its occurrence. The common morphological presentation is gradually progressive cutaneous plaques with variable amount of ulceration and scarring.[13,17] The disease course can run into years, with a risk of dissemination of the fungi to vital organs.

**Secondary Cutaneous Mucormycosis**

Secondary cutaneous mucormycosis is the most common type of cutaneous mucormycosis usually seen in hospital and emergency settings and affects terminally ill and severely immunocompromised patients.[14] The cutaneous involvement in this instance is secondary to dissemination from an internal source. The prevalence of secondary cutaneous mucormycosis is increasing due to prolonged hospital stays, indiscriminate use of antimicrobials, use of chemotherapy and cytotoxic agents and uncontrolled diabetes mellitus. The cutaneous morphology is similar to acute necrotising mucormycosis and can present as erythematous to livid plaques, pustules, retiform lesions, and progressive ulcers.

**Contiguous Mucormycosis**

The cutaneous involvement in this type of mucormycosis is due to contiguous spread from the underlying structures. The well-known form of contiguous mucormycosis is rhino-cerebral mucormycosis. This variant can present with oral ulcers, mucosal eschars, periorbital edema, periorbital cellulitis, opthalmoplegia, loss of vision, and neurological deficits.[18]

The majority of cases of CAM reported have been of rhino-orbito-cerebral mucormycosis in which nose/sinus involvement occurs relatively early in the course of infection whereas eye and intracranial infection occur in the advanced disease. Contiguous involvement subsequent to sinus/nose involvement can occur in the form of pain/loss of sensation on the face, localized facial puffiness, or necrosis of the skin over the cheek, eye or lateral nasal wall area.[17]

**Diagnosis and Treatment of Mucormycosis**

Mucormycosis can be easily diagnosed based on clinical and radiological signs along with microbiological or histopathological evidence of asperate hyphae in the tissues.[19] Unlike diagnosis of COVID-19, molecular diagnosis is not generally recommended as its sensitivity and specificity are lower than the direct microscopy, culture, and histopathology. For cutaneous and subcutaneous mucormycosis, direct microscopic examination using

| Table 1: Classification of cutaneous mucormycosis (adopted from Vinay et al.[13]) |
|---------------------------------------------------------------|
| **Primary cutaneous mucormycosis:** Caused by inoculation of causative organism into the damaged skin |
| **Acute necrotising mucormycosis** |
| **Chronic granulomatous mucormycosis** |
| **Secondary cutaneous mucormycosis:** Secondary involvement of the skin due to haematogenous dissemination from another organ system |
| **Contiguity mucormycosis:** Involvement of the skin due to contiguous spread, mainly from rhinocerebral mucormycosis. |

| Table 2: Clinical and histopathological differences between acute necrotising mucormycosis and chronic granulomatous mucormycosis (adopted from Vinay et al.[13]) |
|---------------------------------------------------------------|
| **Onset** | Acute | Chronic |
| **Progression** | Rapid | Slow |
| **Cellular immunity** | Usually impaired | Usually intact |
| **Causative organism** | Rhizopus, Mucor | Rhizomucor |
| **Mode of involvement** | Traumatic inoculation, Haematogenous dissemination, Contiguous spread | Traumatic inoculation |
| **Clinical features** | Reddish purple indurated plaques progressing to necrosis and eschar formation | Erythematous plaque with a progressive margin and areas of healing and scar formation |
| **Angioinvasion** | Present | Absent |
| **Histolopathology** | Necrotising inflammation | Granulomatous inflammation |
| **Treatment** | Control of predisposing condition, surgical debridement and liposomal amphotericin B | Liposomal amphotericin B |
| **Prognosis and mortality** | Poor can lead to mortality | Good, no mortality but causes significant morbidity |
potassium hydroxide mount with or without calcofluor stain or histopathological examination is preferred. Molecular diagnosis such as polymerase chain reaction (PCR) using Mucorales specific primers are generally recommended for the pulmonary mucormycosis for identification of etiological agent from formalin-fixed paraffin-embedded tissue.\textsuperscript{19‑21}

Surgical removal of all infected tissue is essential for the successful management of mucormycosis. For the medical management of any form of the infection, liposomal amphotericin is the recommended first line of therapy.\textsuperscript{[19]} Posaconazole and isavuconazole may be used as an alternative when liposomal amphotericin B is not available or as a salvage therapy when the patient is intolerant or not responding to amphotericin B.\textsuperscript{[19]} In resource-poorn settings, amphotericin B deoxycholate can also be used as first-line therapy.\textsuperscript{[4]} Though the \textit{in vitro} activity of itraconazole is comparable to other azoles, no trial has been done to evaluate its efficacy in mucormycosis.\textsuperscript{[6,22]}

The current COVID-19 pandemic and the concurrent surge of mucormycosis have given us a glimpse of the larger scenario we may face in the later part of the century. Increasingly older population, extended survival of immunocompromised hosts, and indiscriminate use of antimicrobials has led to an upsurge of systemic fungal infections. The medical community including dermatologists should be well aware of clinical presentations and be prepared to tackle increasing number of common and uncommon fungal infections.

\textbf{Keshavamurthy Vinay, Shivaprasakh M. Rudramurthy\textsuperscript{1}, Sunil Dogra}

\textit{Department of Dermatology, Venerology and Leprology,\textsuperscript{1}Mycology Division, WHO Collaborating Center and Center of Advanced Research in Medical Mycology, Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India}

\textit{Address for correspondence:}

Dr. Sunil Dogra,

Editor-in-chief, Indian Dermatology Online Journal, Professor, Department of Dermatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh - 160 012, India.

E-mail: sundogra@hotmail.com

\textbf{References}

1. Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms 2021;9:523.

2. Shields BE, Rosenbach M, Brown-Joel Z, Berger AP, Ford BA, Wanat KA. Angular invasive fungal infections impacting the skin. J Am Acad Dermatol 2019;80:869-80.e5.

3. Bell S, Mahoney L. Mucormycosis: A case study. Crit Care Nurse 2000;20:18-23.

4. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi 2019;5:26.

5. Skiada A, Petrikkos G. Cutaneous zygomycosis. Clin Microbiol Infect 2009;15:41-5.

6. Rudramurthy SM, Hoenigl M, Meis JF, Cornely OA, Muthu V, Gangneux JP, et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low-and middle-income countries Mycoses. 2021. doi: 10.1111/myc.13335. Epub ahead of print.

7. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis 2021;27. doi: 10.3201/eid2709.210934.

8. Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect 2020;26:944.e9-e15.

9. Galván Casas C, Catalá A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: A rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020;183:71-7.

10. Bogdanov G, Bogdanov I, Kazandjieva J, Tsankov N. Cutaneous adverse effects of the available COVID-19 vaccines. Clin Dermatol 2021, doi: 10.1016/j.clindermat.2021.04.001.

11. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol 2021;85:46-55.

12. Johnston MS, Galan A, Watsky KL, Little AJ. Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine. JAMA Dermatol 2021;157:16-20.

13. Vinay K, Chandrasegaran A, Kanwar AJ, Saikia UN, Kaur H, Shivapraerkash MR, et al. Primary cutaneous mucormycosis presenting as a giant plaque: Uncommon presentation of a rare mycosis. Mycopathologia 2014;178:97-101.

14. Bonifaz A, Tirado-Sánchez A, Hernández-Medel ML, Kassack JJ, Araiza J, González GM. Mucormycosis with cutaneous involvement. A retrospective study of 115 cases at a tertiary care hospital in Mexico. Australas J Dermatol 2021;62:162-7.

15. Sahni K, De D, Dogra S, Kanwar A, Saikia UN, et al. Cutaneous mucormycosis: A fatal complication of immunosuppressant therapy for pemphigus vulgaris. Skinnmed 2017;15:467-9.

16. Lu XL, Liu ZH, Shen YN, She XD, Lu GX, Zhan P, et al. Primary cutaneous zygomycosis caused by rhizomucor variabilis: A new endemic zygomycosis? A case report and review of 6 cases reported from China. Clin Infect Dis 2009;49:e39-43.

17. Castrejón-Pérez AD, Welsh EC, Miranda I, Ocampo-Candiani J, Welsh O et al. Cutaneous mucormycosis. An Bras Dermatol 2017;92:304-11.

18. Mallis A, Mastromikolis SN, Naxakis SS, Papadas AT. Rhinocerebral mucormycosis: An update. Eur Rev Med Pharmacol Sci 2010;14:987-92.

19. Hoenigl M, Salvant-Garcia J, Walsh TJ, Nucci M, Neoh CF, Jenks JD, et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019;19:e405-21.

20. Jiliwin J, Rudramurthy SM, Singh S, Bal A, Das A, Radotra B, et al. Molecular identification of pathogenic fungi in formalin-fixed and paraffin-embedded tissues. J Med Microbiol 2020;70. doi: 10.1099/jmm.0.001282.

21. Zaman K, Rudramurthy SM, Das A, Panda N, Honnavar P, Kaur H et al. Molecular diagnosis of rhino-orbito-cerebral mucormycosis from fresh tissue samples. J Med Microbiol 2017;66:1124-9.

22. Espinel-Ingroff A, Chakraborti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P, et al. Multicenter evaluation of MIC
distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother 2015;59:1745-50.

How to cite this article: Vinay K, Rudramurthy SM, Dogra S. Emergence of mucormycosis during COVID-19 pandemic and dermatological manifestations. Indian Dermatol Online J 2021;12:493-6.

Received: 23-Jun-2021. Accepted: 29-Jun-2021. Published: 14-Jul-2021

© 2021 Indian Dermatology Online Journal | Published by Wolters Kluwer - Medknow